NewLink Genetics Corporation

    [td_text_with_title custom_title=”NewLink Genetics Corporation”]NewLink Genetics was established in 1999 by Dr Charles Link and Dr Nick Vahanian, who realized that immunotherapy was the future direction in cancer treatment. Early work in this area was focused on overcoming either the failure of the immune system to recognize cancer or the ability of the tumor to suppress the immune system. However, NewLink Genetics foresaw that the true potential of cancer immunotherapy would come from addressing both of these immune system deficits.

    Spurred on by these insights, the company set its sights on the development of different technologies that could stimulate an antitumor response or address tumor-related immunosuppression—a combined effort that could provide the greatest chance of treatment success.

    NewLink Genetics is now a publicly traded company of over 100 employees on the verge of bringing new cancer immunotherapies to physicians and patients. In addition to the core group of scientists, some of whom came from the National Cancer Institute, seasoned professionals in product development, marketing, regulatory affairs, and manufacturing are in place to help lead NewLink Genetics toward the launch of its first commercial product.

    NewLink Genetics is based in Ames, Iowa, because of its Midwestern culture and values, as well as the competitive advantage of having easy access to a highly trained, stable work force. NewLink Genetics is located in Iowa State University Research Park, putting them in close proximity to top-rated chemistry programs, graduate students, and other resources. In the near future, NewLink Genetics plans to expand its commercial operations.[/td_text_with_title]

    Drugs

    Dorgenmeltucel-L

    Dorgenmeltucel-L is an investigational HyperAcute™ for melanoma. The product consists of melanoma cell lines that have been genetically modified to express alpha-gal carbohydrates on cell surface molecules. Upon injection into the patient, the alpha-gal stimulates an immune response against melanoma-specific antigens in the tumor cell lines. The patient's immune system then targets their own melanoma cells, destroying them. A [...]
    0 comments

    Tergenpumatucel-L

    Tergenpumatucel-L is an investigational HyperAcute™ for non-small cell lung cancer (NSCLC). The product consists of 3 NSCLC cell lines that have been genetically modified to express alpha-gal carbohydrates on cell surface molecules. Upon injection into the patient, the alpha-gal stimulates a rapid and powerful immune response against NSCLC-specific antigens in the tumor cell lines. The patient’s immune system [...]
    0 comments
    [td_text_with_title custom_title=”Latest post”]

    Posts not found

    [/td_text_with_title]